Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 5Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Oropharyngeal Neoplasms 2Rectal Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoid Interstitial Pneumonia 1Locally Recurrent Skin Squamous Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 70Leucovorin 66Oxaliplatin 50Irinotecan 32Cetuximab 23Bevacizumab 20Capecitabine 16Chemotherapy, Adjuvant 15Folfox protocol 13sargramostim 7Neoadjuvant Therapy 7Erlotinib Hydrochloride 7aldesleukin 5Trastuzumab 5Melphalan 5Magnetic Resonance Spectroscopy 5Gene Expression Profiling 5Floxuridine 5Biopsy 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5dehydroftorafur 4Specimen Handling 4Polymerase Chain Reaction 4Interferon-alpha 4Immunoglobulin G 4Gemcitabine 4Gefitinib 4Disulfides 4Cyclophosphamide 4fludarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Colonic Neoplasms × (225)Ac-DOTA-c(RGDyK) × Clear all
NCT05308446 2026-06-03

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

National Cancer Institute (NCI)

Phase 2 Active not recruiting
86 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡